Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.

Are you looking for our logo? You can download our logo and get information about how to use it on our sharing page

Articles with the topic: gene-silencing

New tool to measure outcomes in Huntington’s Disease clinical trials

New tool to measure outcomes in Huntington’s Disease clinical trials

Megan Krench on September 03, 2015

When patients participate in clinical trials, there needs to be some type of readout to determine whether the new treatment worked. It’s important to know two key things: What to measure and how to measure it. In the case of HD, these obstacles have vexed scientists and doctors for years. The latest research comes up with a clever new approach to overcome both challenges in a new way. These results could offer a valuable tool to study new HD therapeutics entering clinical trials.

Measuring harmful huntingtin protein in the brain’s bath water

Measuring harmful huntingtin protein in the brain’s bath water

Dr Michael Orth on May 18, 2015

Exciting technologies such as gene silencing are being developed for the treatment of Huntington’s disease. Aside from waiting for disease progression to take place, how will we know whether they are working? This has been a major hurdle for HD researchers, but we now have a super-sensitive method to measure the build-up of harmful huntingtin protein in the nervous systems of HD patients.

2015 Huntington's Disease Therapeutics Conference: Day 2

2015 Huntington's Disease Therapeutics Conference: Day 2

Dr Jeff Carroll on February 26, 2015

Our second update from the Annual Huntington's Disease Therapeutics Conference.

Huntington's disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015

Huntington's disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015

Leora Fox on November 04, 2014

A new clinical trial just announced for 2015 aims to test a “huntingtin lowering” therapy, called an antisense oligonucleotide (ASO), that attacks mutant huntingtin directly. We’re extremely excited—it’s the first-ever human HD trial to fight HD at the root of the problem, and has shown great promise in animal models. What’s the scoop?

Could a 'brain shuttle' get Huntington's disease drugs to where they're needed?

Could a 'brain shuttle' get Huntington's disease drugs to where they're needed?

Dr Jeff Carroll on January 20, 2014

Pharmaceutical giant Roche recently described a new drug delivery technology they call the 'brain shuttle'. Why has Huntington's disease been mentioned in so many press releases about this technology, and how much can we hope to gain from this new advance?

'Buzzilia' from the Huntington's Disease World Congress: day 4

'Buzzilia' from the Huntington's Disease World Congress: day 4

Dr Jeff Carroll on September 18, 2013

Our final report from the last morning of the World Congress on Huntington's Disease in Rio de Janeiro, Brazil.

Gene silencing drug safe in ALS patients... bring on Huntington's disease trials

Gene silencing drug safe in ALS patients... bring on Huntington's disease trials

Joseph Ochaba on June 29, 2013

Gene silencing drugs, which tell cells to stop making the harmful huntingtin protein, are among the top approaches being worked on to fight Huntington's disease. A human trial in motor neuron disease using 'ASO' gene silencing drugs has just shown the drugs and delivery method to be safe, boosting plans to get clinical trials of these drugs up and running in HD.

HD Therapeutics Conference 2013 Updates: Day 2

HD Therapeutics Conference 2013 Updates: Day 2

Dr Ed Wild on April 10, 2013

Our second daily report from the annual Huntington's Disease Therapeutics Conference in Venice, Italy. You can tweet @HDBuzzFeed, comment on Facebook or use HDBuzz.net to send us questions, comments and queries.

Major Roche-Isis deal boosts Huntington's disease gene silencing

Major Roche-Isis deal boosts Huntington's disease gene silencing

Dr Ed Wild on April 09, 2013

Isis Pharmaceuticals and Roche have announced a multi-million dollar deal to support the development of 'gene silencing' drugs to human trials. This is big news that secures the future of these exciting drugs for Huntington's disease.